Category Archives: Corporate

Biosceptre appoints new Chief Scientific Officer

Appointment to accelerate commercialisation of lead products

Cambridge, UK, 20 October 2014. Biosceptre, the oncology company developing antibody products that target the nf-P2X7 receptor announces the appointment of Dr Shaun McNulty as Chief Scientific Officer (CSO).

Shaun’s appointment follows an organisational change as the Company progresses from product development to the next phase of product commercialisation. Shaun’s primary function will be to ensure that Biosceptre delivers successful clinical trials for BIL-010t (topical) and BIL-03s (systemic) anti-cancer programmes. The Directors of Biosceptre are pleased to announce the appointment of Shaun as CSO with immediate effect.

Shaun has a wealth of relevant leadership experience including over 18 years of managing development projects and teams within the Pharmaceutical and Biotechnology sectors. Shaun has held leadership positions at GSK, Syntaxin, and Pfizer, where he helped develop Lyrica pregabalin, to treat neuropathic pain and partial seizures. He has consulted for the Biotechnology sector over a 12 year period and has published broadly.

Shaun said: “I am pleased to become CSO at this exciting stage for Biosceptre, with the opportunity to progress human clinical trials to validate our positive findings from preclinical and clinical studies.”

Gavin Currie CEO, added: “I am delighted that Shaun has agreed to become CSO of Biosceptre. His wealth of experience will be enormously beneficial in taking Biosceptre’s programmes forward into the clinic and beyond.”

Media contact:

Daniel Barton
Biosceptre
media@biosceptre.com
+61 412 548 824
+1 650 249 4977

Biosceptre publishes preclinical data on nf-P2X7 in the Journal of Clinical and Cellular Immunology

Paper concludes Biosceptre’s target nf-P2X7 is ubiquitous to all cancer types

Cambridge, UK, 18 July 2014. Biosceptre, the oncology company developing antibody products that target the nf-P2X7 receptor, announces it has published preclinical research on its fully IP-protected cancer target.

For full text of the paper, click here: Non-Functional P2X7: A Novel and Ubiquitous Target in Human Cancer

The paper proposes that a key hurdle to the development of cancer therapies is identifying a target that is common to all cancers, but not found in healthy tissue. Using histological and staining techniques, the researchers tested many different cases and forms of prostate, skin, breast, bowel, ovarian, cervical, uterine, lung, liver, stomach, bladder, head and neck, testicular, and pancreatic cancer tissues for the presence of nf-P2X7.

The results showed nf-P2X7 to be present in all of these cancers; and importantly not present in comparitive healthy tissues. As such the researchers concluded that nf-P2X7 has the potential to provide a novel and broad therapeutic cancer target.

“In our minds, the results from this research couldn’t be clearer,” said Gavin Currie, CEO of Biosceptre. “This is significant data showing our proprietary target to be present in a wide range of cancer types, and is a commercially viable therapeutic target as it is not present in healthy tissues. We look forward to reporting on our topical and systemic clinical programmes that are already underway.”

Media contact:

Daniel Barton
Biosceptre
media@biosceptre.com
+61 412 548 824
+1 650 249 4977

Biosceptre secures Technology Strategy Board Award

Award to develop new therapeutic antibodies targeting nf-P2X7 to treat cancer

Cambridge, UK, 16th July 2014. Biosceptre International Limited, the oncology company developing antibody products that target the nf-P2X7 receptor, today announced it has secured a Technology Strategy Board Feasibility Study Award of £150k. This grant will allow Biosceptre to undertake a feasibility study to expand its pipeline of monoclonal antibodies (mAbs) to bind the nf-P2X7 receptor, a non-functioning conformation of the P2X7 receptor, for the treatment of cancer. This is the first Technology Strategy Board award that Biosceptre has secured since relocating to the UK in February 2014.

The project aims are to develop a series of mAbs, confirm their ability to bind nf-P2X7, and demonstrate in vitro cytotoxicity. Work is due to start on the project in July 2014.

Shaun McNulty, Commercial Manager, who secured the grant application said: “Feedback from the Technology Strategy Board reviewers highlighted Biosceptre’s strength of scientific approach, the fundamental technology, and potential for commercialisation as key factors in selecting us for the award.”

“We are delighted to have secured this funding through the Technology Strategy Board,” said Gavin Currie, CEO of Biosceptre. “This grant will enable the Company to further explore and develop new potential products to diagnose and treat cancer, taking advantage of our unique intellectual property position and proprietary knowledge of the nf-P2X7 receptor.”

Media contact:

Daniel Barton
Biosceptre
media@biosceptre.com
+61 412 548 824
+1 650 249 4977

Biosceptre moves corporate headquarters to the UK from Australia

Move provides greater access to investors, grants, partners and expertise

Cambridge, UK, 21st February 2014. Biosceptre International Limited, the oncology company developing antibodies to target the nf-P2X7 receptor, today announced that has moved operations to the UK, from Australia.

The move comes as Biosceptre enters the next phase of its development. The Company is currently progressing the applications of its unique intellectual property and knowledge of nf-P2X7, including systemic and topical applications for human and veterinary use, across therapeutics, diagnostics and imaging, and immuno-oncology vaccines.

“The move to the UK, in particular Cambridge, gives Biosceptre access to some of the greatest expertise in antibody engineering in the world. This, combined with greater access to capital, European grants, the favourable taxation position for R&D companies, and potential developmental partners on our doorstep, will provide Biosceptre with the greatest chance of commercial success,” said Gavin Currie, CEO of Biosceptre.

Following the move to the UK, Biosceptre will have its headquarters and main research facility in Cambridge, but will also maintain the existing facilities in Sydney, Australia.

Media contact:

Daniel Barton
Biosceptre
media@biosceptre.com
+61 412 548 824
+1 650 249 4977